
	Mr. Gregory D. Perry, also known as Greg, has been Chief Financial &amp; Business Officer and Principal Accounting Officer at Eleven Biotherapeutics, Inc. since December 2013. Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics Holdings Corp. from September 23, 2013 to December 30, 2013. He served as the Chief Financial Officer of ImmunoGen, Inc. from 2009 to September 13, 2013 and served as its Executive Vice President from April 2011 to September 13, 2013. Mr. Perry served as the Principal Accounting Officer of ImmunoGen, Inc. and served as its Treasurer until September 13, 2013 and July 2011 respectively. He served as Senior Vice President of ImmunoGen from January 2009 to April 2011. He served as the Chief Financial Officer of Domantis Limited since June 27, 2006. Mr. Perry served as Chief Financial Officer of Shire Human Genetic Therapies Inc. (formerly, Transkaryotic Therapies Inc.) from May 27, 2003 to 2005 and served as its Principal Accounting Officer. He served as the Chief Financial Officer of Elixir Pharmaceuticals, Inc. from January 29, 2007 to 2009 and served as its Chief Accounting Officer and Executive Vice President. Mr. Perry served as Senior Vice President of Shire Human Genetic Therapies Inc. from November 12, 2004 to 2005 (Transkaryotic Therapies Inc. is acquired by Shire Pharmaceuticals Group plc in 2005). He served as Vice President of finance of Shire Human Genetic Therapies Inc. from May 27, 2003 to November 12, 2004. He was responsible for all financial matters of Shire Human Genetic Therapies Inc. and has a twenty year record of demonstrated financial success in quality organizations. He joined Transkaryotic in May 2003. He served as Senior Vice President, Finance and Business Development of Life Sciences at PerkinElmer Inc. from October 1998 to November 2002. He was responsible for Financial management of PerkinElmer&#39;s drug discovery tools and genetic disease screening business, as well as information technology and business development activities. Prior to PerkinElmer, Mr. Perry served as Chief Financial Officer of Automotive Aftermarket Products Group at Honeywell where he played a major role in rebuilding their finance team and successfully closed the acquisition of Prestone Products. He served as Chief Financial Officer, Europe of GE Healthcare and during his fourteen-year tenure at General Electric, he served numerous positions of increasing responsibility in finance and business development. He has been a Director of Advanced Cell Technology Inc. since December 6, 2011. He served as a Director of Sucampo Pharmaceuticals Inc. from May 2006 to September 2006. He served as a Director of Shire Human Genetic Therapies Inc. Mr. Perry holds a BA degree in Economics and Political Science from Amherst College.
